Table 1.
Sociodemographic and clinical characteristics of HIV/hepatitis C virus (HCV)-coinfected patients at baseline according to whether they progressed to significant liver fibrosis [aspartate aminotransferase to platelet ratio index (APRI) ≥ 1.5] in follow-up
| Total (n = 288) | Progressors (n = 57) | Nonprogressors (n = 231) | |
|---|---|---|---|
| Follow-up time (years) [median (IQR)] | 1.5 (0.7, 2.9) | 1.0 (0.5, 1.9) | 1.8 (0.9, 3.0) |
| Age (years) [median (IQR)] | 45 (40, 50) | 46 (42, 51) | 45 (40, 50) |
| Female [n (%)] | 75 (26) | 15 (26) | 60 (26) |
| Aboriginal [n (%)] | 40 (14) | 6 (11) | 34 (15) |
| IDU ever [n (%)] | 236 (82) | 51 (89) | 185 (80) |
| IDU in previous 6 months [n (%)] | 90 (31) | 16 (28) | 74 (32) |
| Current alcohol use [n (%)] | 148 (51) | 32 (56) | 116 (50) |
| Current alcohol abuse* [n (%)] | 41 (28) | 13 (42) | 28 (24) |
| Time since HIV diagnosis (years) [median (IQR)] | 12 (7, 17) | 11 (7, 15) | 12 (7.6, 18) |
| Duration of HCV infection (years) [median (IQR)] | 19 (11, 27) | 20 (12, 28) | 19 (11, 26) |
| Nadir CD4 count (cells/μL) [median (IQR)] | 150 (50, 249) | 158 (84, 264) | 150 (50, 240) |
| CD4 count (cells/μL) [median (IQR)] | 440 (298, 609) | 419 (249, 642) | 440 (305, 602) |
| HIV RNA load (copies/mL) [median (IQR)] | 49 (39, 49) | 49 (39, 49) | 49 (39, 49) |
| APRI [median (IQR)] | 0.5 (0.4, 0.8) | 0.8 (0.5, 1.1) | 0.5 (0.4, 0.7) |
| On cART [n (%)] | 277 (96) | 55 (96) | 222 (96) |
| cART regimen† [n (%)] | |||
| PI | 198 (69) | 47 (82) | 151 (65) |
| NNRTI | 82 (28) | 9 (16) | 73 (32) |
| Others | 16 (6) | 1 (2) | 15 (6) |
| HCV RNA (log10 copies/mL) [median (IQR)]‡ | 6.2 (5.4, 6.8) | 6.5 (5.3, 6.8) | 6.2 (5.4, 6.7) |
| HCV treatment naïve [n (%)] | 253 (88) | 48 (84) | 205 (89) |
cART, combination antiretroviral therapy; IDU, injecting drug use; PI, protease inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor.
Alcohol abuse was defined as self-reported alcohol intake of more than two drinks per day or binge drinking (greater than six drinks at any one time). †Sum of regimens >100% as some participants are on both PI, NNRTI and/or other cART. ‡For HCVRNA, only 114 [26/57 (46%) progressors and 88/231 (38%) non-progressors] had available quantitative HCV RNA values.